# A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

> **NCT05773040** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 33 (estimated)

## Conditions studied

- Lymphomas
- B-cell Lymphomas

## Interventions

- **DRUG:** JV-213
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT05773040
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-14
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05773040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05773040, "A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05773040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*